"Antibodies, Viral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins produced in response to VIRAL ANTIGENS.
| Descriptor ID |
D000914
|
| MeSH Number(s) |
D12.776.124.486.485.114.254 D12.776.124.790.651.114.254 D12.776.377.715.548.114.254
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Viral".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Viral".
This graph shows the total number of publications written about "Antibodies, Viral" by people in this website by year, and whether "Antibodies, Viral" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 2 | 3 |
| 2012 | 0 | 2 | 2 |
| 2013 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 1 | 2 | 3 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 3 | 3 |
| 2024 | 7 | 2 | 9 |
| 2025 | 1 | 3 | 4 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Viral" by people in Profiles.
-
Immune correlates of risk for SARS-CoV-2 infection in children: a prospective, community-based cohort study. Nat Commun. 2026 Jul 18; 17(1).
-
Newborn IgG and IgM antibodies to maternal SARS-CoV-2 infection in pregnancy and child neurodevelopmental outcomes. Brain Behav Immun. 2026 Aug; 136:106591.
-
Durability of the Mumps Antibody Response After the Third Dose of MMR Vaccine. J Infect Dis. 2026 Feb 18; 233(2):e383-e391.
-
Correlates of risk of respiratory syncytial virus disease: a prospective cohort study. Nat Commun. 2025 Sep 26; 16(1):8490.
-
Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel. Vaccine. 2025 Aug 13; 61:127361.
-
SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020-July 2022. Am J Epidemiol. 2025 Jun 03; 194(6):1574-1583.
-
Safety profile of self-amplifying mRNA SARS-CoV-2 vaccine ARCT-154 in adults: a pooled phase 1/2/3 randomized clinical study. Expert Rev Vaccines. 2025 Dec; 24(1):299-312.
-
Risk reduction in SARS-CoV-2 infection and reinfection conferred by humoral antibody levels among essential workers during Omicron predominance. PLoS One. 2024; 19(12):e0306953.
-
Molecular features of the serological IgG repertoire elicited by egg-based, cell-based, or recombinant haemagglutinin-based seasonal influenza vaccines: a comparative, prospective, observational cohort study. Lancet Microbe. 2025 Feb; 6(2):100935.
-
Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).